CAR T cell therapy for relapsed myeloma with multiple targets
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or treatment-resistant multiple myeloma that has CD138 and/or BCMA markers
- You have no curative treatment options (like stem cell transplant) available
- Your disease has returned after a prior stem cell transplant (autologous or allogeneic)
- You need to be well enough to travel through treatment: expected survival at least 3 months, good heart/lung function, and good liver/kidney and blood clotting labs
- You must be able to safely donate cells for the process (apheresis/collection) and have no major reasons you cannot receive leukapheresis
- You generally must not have had chemo in the last month and not immunotherapy in the last 3 months before the CAR T cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests an investigational drug for people with multiple myeloma that has returned after a stem cell transplant from a donor. It aims to see if the drug can help control the cancer when other treatments haven't worked.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.